MEwens
The FDA said today it approved the Swiss drug maker’s Gilenya (known generically as fingolimod) for use against the most common type of MS.
Read more this great post here
Continued Read ...
Laura Landro
Also: Most C-sections performed before labor starts; American companies push into Chinese electronic medical record market; investigators looking at health-care credit cards.
Read more this great post here
Continued Read ...
Katherine Hobson
Also: a $1.3 billion health IT merger; abortion-inducing pills via telemedicine in Iowa.
Read more this great post here
Continued Read ...
JGrimes
A simple test blood could help doctors determine which multiple-sclerosis patients will respond to the top-selling MS drug, sparing patients not likely to benefit the cost and flu-like symptoms connected with the treatment.
A study led by Stanford researchers said that sorting between those likely and unlikely to respond to the drug beta-interferon was […]
Continued Read ...
JGrimes
Carl Icahn and Biogen Idec agreed to avoid another proxy flight as the biotech gave its backing for a third Icahn representative to join its board. But if it sounds like the long-time activist is taking a new tack on Biogen, guess again.
“At the right price, I think Biogen should be sold,” Icahn […]
Continued Read ...
noreply@blogger.com (RCoffield@fsblaw.com)
Generic maker Teva Pharmaceutical posted higher quarterly results that included stronger sales of its branded multiple sclerosis treatment Copaxone.
The Israeli company will save “hundreds of millions of dollars” starting later this year after it ends royalty payments of 25% on U.S. sales of Copaxone that it has been making to Sanofi-Aventis, Teva’s […]
Continued Read ...
noreply@blogger.com (RCoffield@fsblaw.com)
The FDA just approved a new multiple sclerosis drug called Ampyra. The drug (also known as Fampridine-SR) helps some patients walk faster.
Trouble walking is a serious problem for many MS patients. But only a minority of patients seem to benefit from Ampyra. In one study, 35% of people who took the drug […]
Continued Read ...
noreply@blogger.com (RCoffield@fsblaw.com)
Here’s a quick roundup of some news on experimental drugs:
Two pills for multiple sclerosis fared well in clinical trials published this week in the New England Journal of Medicine. One, Novartis’s fingolimod, was tested against a placebo and against Avonex, a form of interferon sold by Biogen Idec. The other, Merck KGaA’s […]
Continued Read ...
JGrimes
An experimental multiple sclerosis drug many not help most of the patients who take it, an FDA advisory panel said yesterday. But a benefit for a minority of patients was enough to convince the panel to vote in favor of fampridine-SR, Dow Jones Newswires reports.
Shares of Acorda Therapeutics, a small company that’s developing […]
Continued Read ...
Jacob Goldstein
Shares of a small New York drug maker plunged today after FDA staff raised concerns about its multiple sclerosis drug, the first pill intended to help those suffering from the chronic condition to walk faster.
The ups and downs of stock in the drug maker, Acorda Therapeutics, are all too familiar for anyone […]
Continued Read ...
